Last reviewed 2026-06-02 · How we verify

Cyklokapron (TRANEXAMIC ACID)

Cyklokapron (generic name: TRANEXAMIC ACID) is a Antifibrinolytic Agent [EPC] Small molecule drug developed by Exela Pharma. It is currently FDA-approved (first approved 1986) for Contraception, Endometriosis, Female hypogonadism syndrome.

Tranexamic acid works by binding to plasminogen and preventing its conversion to plasmin, thereby inhibiting fibrinolysis.

Cyklokapron, also known as tranexamic acid, is a small molecule that inhibits plasminogen, a protein involved in blood clot breakdown. It is used to treat or prevent conditions such as blood loss, postoperative complications, and osteoarthritis knee pain.

At a glance

Mechanism of action

Tranexamic acid is synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrins matrix structure.The antifibrinolytic effects of tranexamic acid are mediated by reversible interactions at multiple binding sites within plasminogen. Native human plasminogen contains to lysine binding sites with low affinity for tranexamic acid (Kd 750 umol/L) and with high affinity (Kd 1.1 umol/L). The high affinity lysine site of plasminogen is involved in its binding to fibrin. Saturation of the high affinity binding site with tranexamic acid displaces plasminogen from the surface of fibrin. Although plasmin may be formed by conformational changes in plasminogen, binding to and dissolution of the fibrin matrix is inhibited.

Approved indications

• Contraception
• Endometriosis
• Female hypogonadism syndrome
• Hemorrhaging in Hemophilia
• Menorrhagia

Common side effects

• Thromboembolic events
• Convulsion
• Chromatopsia
• Visual impairment
• Anaphylaxis or anaphylactoid reaction
• Hypotension
• Giddiness
• Allergic dermatitis
• Nausea
• Vomiting
• Diarrhea

Drug interactions

• tretinoin

Key clinical trials

• Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma (NA)
• Tranexamic Acid for The Treatment of Gastrointestinal Bleeding (NA)
• Hemoglobin Drop and Need for Blood Transfusion in Primary Knee Arthroplasty With or Without Drain Insertion (NA)
• Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty (NA)
• Prevention of Postpartum Hemorrhage With Tranexamic Acid (PHASE2)
• Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
• Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
• The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Cyklokapron CI brief — competitive landscape report
• Cyklokapron updates RSS · CI watch RSS
• Exela Pharma portfolio CI

Frequently asked questions about Cyklokapron

Related

• Drug class: All Antifibrinolytic Agent [EPC] drugs
• Target: All drugs targeting Plasminogen
• Manufacturer: Exela Pharma — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Contraception
• Indication: Drugs for Endometriosis
• Indication: Drugs for Female hypogonadism syndrome

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing